Search research articles
Contact Us
Filters
Showing results (61-70 of 108) with videos related to
Page
of 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 31, 2010
Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy
Maciej Krzakowski, Rodryg Ramlau, Jacek Jassem, et al.
Molecular Cancer
|
January 28, 2014
Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer
Daniel S W Tan, Benjamin Haaland, Jia Min Gan, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2015
Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer
Eng Huat Tan, Daniel Shao Weng Tan, Wen Yun Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 20, 2005
Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety
Joseph Wee, Eng Huat Tan, Bee Choo Tai, et al.
The New England Journal of Medicine
|
July 15, 2005
Erlotinib in previously treated non-small-cell lung cancer
Frances A Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 11, 2021
Intratumoral CD39<sup>+</sup>CD8<sup>+</sup> T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC
Joe Yeong, Lisda Suteja, Yannick Simoni, et al.
Clinical Lung Cancer
|
June 24, 2014
Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01)
Jaafar Bennouna, Libor Havel, Maciej Krzakowski, et al.
Frontiers in Oncology
|
July 26, 2021
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
Antonio Passaro, Filippo de Marinis, Hai-Yan Tu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 4, 2013
Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma
Whay-Kuang Chia, Marissa Teo, Who-Whong Wang, et al.
The Lancet. Oncology
|
March 29, 2012
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A Miller, Vera Hirsh, Jacques Cadranel, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 108) with videos related to
Sort By:
Page
of 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 31, 2010
Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy
Maciej Krzakowski, Rodryg Ramlau, Jacek Jassem, et al.
Molecular Cancer
|
January 28, 2014
Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer
Daniel S W Tan, Benjamin Haaland, Jia Min Gan, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2015
Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer
Eng Huat Tan, Daniel Shao Weng Tan, Wen Yun Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 20, 2005
Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety
Joseph Wee, Eng Huat Tan, Bee Choo Tai, et al.
The New England Journal of Medicine
|
July 15, 2005
Erlotinib in previously treated non-small-cell lung cancer
Frances A Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 11, 2021
Intratumoral CD39<sup>+</sup>CD8<sup>+</sup> T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC
Joe Yeong, Lisda Suteja, Yannick Simoni, et al.
Clinical Lung Cancer
|
June 24, 2014
Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01)
Jaafar Bennouna, Libor Havel, Maciej Krzakowski, et al.
Frontiers in Oncology
|
July 26, 2021
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
Antonio Passaro, Filippo de Marinis, Hai-Yan Tu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 4, 2013
Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma
Whay-Kuang Chia, Marissa Teo, Who-Whong Wang, et al.
The Lancet. Oncology
|
March 29, 2012
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A Miller, Vera Hirsh, Jacques Cadranel, et al.
Page
of 11